A Single dose, two-way crossover study of the bioequivalence of two formulations of Ribaviri

Completed

• Conditions: Hepatitis C; 10019654

• Registration Number: NL-OMON36756
• Lead Sponsor: Schering-Plough

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 54

Inclusion Criteria

18-55 years,
BMI 18-30 kg/m2 (inclusive)
man or postmenopausal women

Exclusion Criteria

Suffering from: hepatitis B, cancer or HIV/Aids. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood (for men) / more than 1.0 liters of blood (for women) in the 10 months preceding the start of this study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Pharmacokinetics<br /><br>Safety<br /><br></p><br>

Secondary Outcome Measures

Name	Time	Method
<p>N/A</p><br>